The most common and costly drugs of 2019–2020


Wednesday, 02 December, 2020

The most common and costly drugs of 2019–2020

Which prescription medicines are most commonly used in Australia? Which have the greatest cost to the Australian Government?

According to figures published in Australian Prescriber — based on PBS and RPBS data — the drugs with the most prescription counts in 2019–2020 were the cholesterol-lowering medications rosuvastatin (12,968,693 prescriptions) and atorvastatin (11,241,737 prescriptions). Medications to reduce stomach acid were the next most common, with pantoprazole and esomeprazole having 8,283,205 and 8,171,291 prescriptions, respectively.

The blood-pressure-lowering drug perindopril and an antibiotic called cephalexin were the next most commonly prescribed medications

Aflibercept — a drug used to treat eye conditions such as macular degeneration — has cost the taxpayer almost $400 million in 2019–2020, topping the list of drugs ranked by cost to government. The drug, which was in second place last year, has topped the chart this year thanks to growing numbers of prescriptions.

Many of the top 10 most expensive drugs are products often referred to as ‘biologicals’, based on monoclonal antibodies. Cholesterol-lowering drugs and blood pressure drugs made up most of the top 10 most commonly used prescription drugs in Australia in 2019–2020.

The antidepressant sertraline (sold under the trade name Zoloft) is a new entry to the list of most commonly prescribed drugs by population.

Click here to access the Top 10 PBS/RPBS drugs by dose, prescription count and cost to government.

Image credit: ©stock.adobe.com/au/Kenishirotie

Related News

Non-invasive 'virtual' biopsy for skin cancer diagnosis

Researchers have developed a new imaging method that allows clinicians to analyse the skin...

UTI vaccines could prevent infection for nine years

MV140 is a new vaccine for recurrent UTIs and is administered with two sprays of a...

What's the key to retaining rural GPs?

Understanding doctors' decisions to stay or leave, once recruited, could provide insights on...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd